Search for: "Key v State"
Results 9321 - 9340
of 22,474
Sorted by Relevance
|
Sort by Date
19 Dec 2015, 8:28 am
Arbino v. [read post]
27 Jul 2011, 10:03 pm
In Kowalski v. [read post]
13 Jul 2009, 3:29 pm
Comment As well as the view on Doherty, which is broadly in line with the limiting decisions in Doran, Central Bedfordshire v Taylor and McGlynn v Hatfield, and also follows the suggestion that period of occupation is the key ‘personal circumstance’, there is an important issue here on evidence of failure to take into account relevant considerations. [read post]
29 Aug 2013, 10:04 am
In so holding, the Ninth Circuit was simply recognizing that the United States Supreme Court’s decision earlier this year in Standard Fire Insurance v. [read post]
4 Jan 2023, 12:34 am
It starts with a case on the open fields doctrine, United States v. [read post]
14 Aug 2013, 6:05 am
The key case on gender stereotyping is the 1989 Supreme Court case Price Waterhouse v. [read post]
9 Nov 2018, 2:13 pm
Note to our Right on Crime friends: We need to see Bernie Kerik v. [read post]
3 Aug 2019, 7:56 am
Hexum v. [read post]
4 Oct 2017, 6:24 am
In the recent decision of Mehta v. [read post]
19 Apr 2012, 11:11 pm
I worried that the round-the-clock coverage of Agni V would detract from the much needed focus on the RTE Act, but today's papers provide some reassurance on this score. [read post]
26 Aug 2017, 5:01 am
In the recent decision of In re: GR Burgr, LLC; GR US Licensing, LP v. [read post]
7 Mar 2019, 2:14 pm
Mahler v. [read post]
6 Apr 2012, 10:13 am
United States v. [read post]
18 Dec 2017, 5:57 pm
Genzyme Corp. v. [read post]
21 Sep 2010, 5:22 am
Richard Smith, et al. v. [read post]
13 Jan 2008, 4:36 am
This evolutionary approach is what I believe holds the key to understanding how to think about law and institutions. [read post]
11 May 2012, 2:18 pm
The briefs in support of the challenge to the individual mandate provisions of the Affordable Care Act assume that United States v. [read post]
29 May 2018, 6:46 pm
” Collins v. [read post]
22 May 2014, 3:58 pm
The agenda includes the following presentations: Minimizing the Uncertainty Surrounding the Untested Pathway: Insight Into FDA's Current Position and Initiatives Regarding Biosimilars Predicting Follow-On Entry and Evaluating the Risk and Commercial Opportunity in the Emerging Biosimilar Landscape New Kid No More: Evolution in Biosimilars Science and Regulations The Holy Grail for Biosimilars: Meeting FDA's Requirements for Biosimilarity and the Heightened Standard of Interchangeability… [read post]
